Tag: MYC

A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors

Cell lines and culture Unless stated otherwise, all tumor target cell lines were sourced from the ATCC via LGC Standards. Human endogenous mesothelin (MSLN)-positive target cell lines H-226 (lung carcinoma, MSLN+, ATCC® CRL-5826™) and AsPC-1 (ATCC CRL-1682), and MSLN-negative Raji control cells (ATCC CCL-86) were cultured in RPMI-1640 Glutamax (Life Technologies,…

Continue Reading A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors

Identification of differentially expressed genes in AF

Defeng Pan,1,* Yufei Zhou,2,* Shengjue Xiao,1,* Yue Hu,3,* Chunyan Huan,1 Qi Wu,1 Xiaotong Wang,1 Qinyuan Pan,1 Jie Liu,1 Hong Zhu1 1Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, People’s Republic of China; 2Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of…

Continue Reading Identification of differentially expressed genes in AF

Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity

Significance Interferon (IFN)-mediated antiviral responses serve as the first line of the host innate immune defense against viral infection. Here we identify a previously uncharacterized protein designated phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein (PINLYP), which is essential for embryonic development and plays an important role in type I IFN…

Continue Reading Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Valine tRNA levels and availability regulate complex I assembly in leukaemia

1. Rapino, F. et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature 558, 605–609 (2018). CAS  PubMed  Google Scholar  2. Goodarzi, H. et al. Modulated expression of specific tRNAs drives gene expression and cancer progression. Cell 165, 1416–1427 (2016). CAS  PubMed  PubMed Central  Google Scholar  3. Wolfe, A….

Continue Reading Valine tRNA levels and availability regulate complex I assembly in leukaemia

Systems biology analysis of human genomes points to key pathways conferring spina bifida risk

Significance Genetic investigations of most structural birth defects, including spina bifida (SB), congenital heart disease, and craniofacial anomalies, have been underpowered for genome-wide association studies because of their rarity, genetic heterogeneity, incomplete penetrance, and environmental influences. Our systems biology strategy to investigate SB predisposition controls for population stratification and avoids…

Continue Reading Systems biology analysis of human genomes points to key pathways conferring spina bifida risk

Vincerx Pharma Presents Data o

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data o

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company…

Continue Reading Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

An Optimized Culture Medium for Induced Pluripotent Stem Cells

In 2006, Kazutoshi Takahashi and Shinya Yamanaka made a revolutionary breakthrough when they reprogrammed terminally differentiated, lineage-restricted adult somatic cells into a pluripotent state via the expression of transcription factors Oct4, Sox2, Klf4, and c-Myc.1 Now, researchers can differentiate reprogrammed induced pluripotent stem cells (iPSCs) into any cell type and…

Continue Reading An Optimized Culture Medium for Induced Pluripotent Stem Cells

BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors…

Continue Reading BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

Double-hit lymphoma: optimizing therapy – Docwire News

This article was originally published here Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. ABSTRACT Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some…

Continue Reading Double-hit lymphoma: optimizing therapy – Docwire News

MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

doi.org/10.1016/j.leukres.2021.106769Get rights and content Highlights • MiR-665 is down-regulated in the serum exosomes from DLBCL patients. • MiR-665 suppresses DLBCL cell proliferation and invasion and induces apoptosis. • LASP1 is a target of miR-665. • MiR-665 regulates DLBCL progression through targeting and inhibiting LASP1. Abstract Diffuse large B cell lymphoma…

Continue Reading MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)

Vincerx Pharma (VINC) Receives Orphan Drug Designation from EC for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s…

Continue Reading Vincerx Pharma (VINC) Receives Orphan Drug Designation from EC for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

Vincerx Pharma Receives Orphan Drug Designation from

PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the…

Continue Reading Vincerx Pharma Receives Orphan Drug Designation from

miRNAs and mRNAs in intestinal ischemia-reperfusion injury

Introduction Intestinal ischemia-reperfusion (II/R) injury is a severe clinical complication common in the Intensive Care Unit (ICU). It is associated with high morbidity and mortality.1 Usually, this problem is followed by various causes, including sepsis, shock, trauma, and so on.2 Intestinal ischemia-reperfusion injury destroys intestinal tissue and impairs the function…

Continue Reading miRNAs and mRNAs in intestinal ischemia-reperfusion injury

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

Identification of Prognosis-Associated Biomarkers in Thyroid Carcinoma

Introduction Thyroid cancer (TC) is a common endocrine malignancy with a rapidly increasing incidence worldwide, and the estimated new cases and deaths are notably higher in women than in men.1 Papillary thyroid carcinoma (PTC) is identified as the most common pathological type of TC, and accounts for approximately 80–85% of…

Continue Reading Identification of Prognosis-Associated Biomarkers in Thyroid Carcinoma

Research reveals a previously unknown role for a key transcription regulator linked to cancer

CTCF is a transcription factor that has been a research target due to its role in regulating a critical oncogene called MYC. Scientists at St. Jude Children’s Research Hospital have found direct evidence that CTCF governs chromatin accessibility, the process of opening tightly spooled DNA so that genes can be…

Continue Reading Research reveals a previously unknown role for a key transcription regulator linked to cancer

Evidence for how a key transcription factor manages access to DNA

Credit: CC0 Public Domain CTCF is a transcription factor that has been a research target due to its role in regulating a critical oncogene called MYC. Scientists at St. Jude Children’s Research Hospital have found direct evidence that CTCF governs chromatin accessibility, the process of opening tightly spooled DNA so…

Continue Reading Evidence for how a key transcription factor manages access to DNA

Research provides evidence for how a key transcription factor manages access to DNA

Newswise — CTCF is a transcription factor that has been a research target due to its role in regulating a critical oncogene called MYC. Scientists at St. Jude Children’s Research Hospital have found direct evidence that CTCF governs chromatin accessibility, the process of opening tightly spooled DNA so that genes…

Continue Reading Research provides evidence for how a key transcription factor manages access to DNA

Nuclear protein in testis carcinoma

Introduction Nuclear protein in testis (NUT) carcinoma (NC) is defined by the rearrangement of the chromosomal region 15q14 harboring the NUTM1 gene. As a clinically aggressive neoplasm with poor differentiation, NC was previously believed to occur primarily in children and young adolescents. However, with an increasing number of reports, middle-aged…

Continue Reading Nuclear protein in testis carcinoma

How to load Seurat Object into WGCNA Tutorial Format

As far as I can find, there is only one tutorial about loading Seurat objects into WGCNA (ucdavis-bioinformatics-training.github.io/2019-single-cell-RNA-sequencing-Workshop-UCD_UCSF/scrnaseq_analysis/scRNA_Workshop-PART6.html). I am really new to programming so it’s probably just my inexperience, but I am not sure how to load my Seurat object into a format that works with WGCNA’s tutorials (horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/Tutorials/)….

Continue Reading How to load Seurat Object into WGCNA Tutorial Format